- A +

Events › 2014


Didier Pruneau, CSO of GenSight, featured at Gene Therapy (Dec. 3-4, 2014,Brussels) and gave a talk on "Translational development of GS010, an ocular mitochondrial gene therapy".

19 - 21Nov.2014

GenSight presented at Therapeutic Area Partnership, in Boston (MA), as Top projects to watch in track #6 Advanced Therapies on Thursday 20, 2.15-2.30 pm.

23 - 26Jun.2014

GenSight Biologics attended BIO, San Diego, CA, USA.


GenSight Biologics won the award of the Investor Conference at BioVision Investor Conference, Lyon, France. 

Read the full press release (in French), Look at the video

21 - 22May2014

GenSight Biologics presented in the the Next wave Companies list at BioEquity, Amsterdam, the Netherlands.

04 - 09May2014

GenSight Biologics attended ARVO annual meeting, Orlando, FL, USA and presented a poster:Safety, local tolerability and biodistribution of GS010 (AAV2/2-ND4), a gene therapy medicinal product in development for Leber Hereditary Optic Neuropathy (LHON)Physiology/Pharmacology, 342 Gene Therapy and Delivery, Poster Number: 3340 - B0280.

10 - 12Mar.2014

GenSight Biologics presented at BioEurope Spring


GenSight Biologics expands its Series A round to the French seed fund for innovative biotherapies and rare diseases.

Read the full press release (available only in French)

13 - 16Jan.2014

GenSight Biologics attended JP Morgan Healthcare Conference and Biotech Showcase, San Francisco, CA, USA.